ORTHO CYCLEN-28
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ortho Cyclen-28 is an oral contraceptive tablet containing norgestimate and ethinyl estradiol, approved in 1989 for pregnancy prevention. It is a combined hormonal contraceptive that prevents ovulation through suppression of gonadotropins. The product is indicated for women seeking reliable, reversible contraception.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting reduced team investment and focus on margin protection rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Ortho Cyclen-28 offers limited career growth potential given the product's LOE-approaching lifecycle stage and zero linked job openings. Roles are primarily defensive, focused on maintaining market share and managing margin erosion in a mature, generic-pressured market rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on ORTHO CYCLEN-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.